Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. Issue 7 (3rd July 2017)

• Record Type: Journal Article
• Authors: Rodgers, Louis; Peer, Cody J.; Figg, William D.
• Is Part Of: Cancer biology & therapy. Volume 18:Issue 7(2017)
• Page Start: 470
• Page End: 472
• Publication Date: 2017-07-03
• Subjects: Biomarkers -- gene expression signature -- genetic testing -- HSD3B1 -- mathematical oncology -- microRNA -- prostate cancer; 616.99406
• DOI: 10.1080/15384047.2017.1323600
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: A lack of appropriate diagnostic tools for prostate cancer has led to overdiagnosis and over treatment. In a recent publication in the New England Journal of Medicine, Hamdy et al showed no difference in the outcomes of patients that had undergone either radical prostatectomy, radiotherapy, or active monitoring. In an effort to enhance clinical stratification, the development of improved, more accurate diagnostic tools is actively being pursued. Herein, we explore recent advances in prostate cancer screening, including biomarker assays, genetic testing, and specialized fields, such as mathematical oncology. These newly developed, highly sensitive diagnostic assays may potentially aid clinicians in selecting appropriate therapies for patients in the very near future.